Suppr超能文献

125 例单一中心肾上腺意外瘤患者的结果。对 1mg 过夜和小剂量地塞米松抑制试验的回顾性评估。

Outcomes in 125 individuals with adrenal incidentalomas from a single centre. a retrospective assessment of the 1 mg overnight and low dose dexamethasone suppression tests.

机构信息

Department of Endocrinology, Royal Free Hampstead NHS Trust, London, United Kingdom.

出版信息

Horm Metab Res. 2011 Dec;43(13):962-9. doi: 10.1055/s-0031-1291249. Epub 2011 Nov 2.

Abstract

Adrenal masses discovered incidentally during imaging studies - adrenal incidentalomas (AIs) - are common and prompt investigations to exclude secretory lesions and malignancy. Their best management strategy is unknown. Our objectives were to identify all outcomes of AI investigation in a UK centre and to assess the performance of the 2 mg low dose (LDDST) and 1 mg overnight dexamethasone (ODST) suppression tests in this setting. Out of 125 patients referred to our centre between 2005 and 2009 with AIs, 16 (12.8%) were diagnosed with secretory adrenal adenomas. 24 patients (23%) failed to suppress on LDDST or ODST using a serum cortisol cut-off of 50 nmol/l for both tests; in 12 this was due to false positive results. 5 patients were diagnosed with adrenal Cushing's syndrome and 7 with subclinical hypercortisolism. The use of a higher post LDDST (83 nmol/l) or ODST (138 nmol/l) cortisol cut-off would have resulted in missing 1 patient with Cushing's syndrome and 4 with subclinical hypercortisolism or 2 patients with Cushing's syndrome and 1 with subclinical hypercortisolism, respectively. In patients who had both tests, the ODST systematically resulted in higher post-test cortisol values compared with the LDDST. The adenoma diameter correlated with and was predictive of the post LDDST cortisol. Our results indicate that altering the post dexamethasone cut-off in accordance to published guidelines changes the performance of the suppression tests. The ODST may result in higher post-test cortisol levels compared to LDDST when used in patients with AIs.

摘要

在影像学研究中偶然发现的肾上腺肿块 - 意外性肾上腺瘤(AIs) - 很常见,需要进行紧急调查以排除分泌性病变和恶性肿瘤。它们的最佳管理策略尚不清楚。我们的目的是确定英国中心所有 AI 调查的结果,并评估 2mg 低剂量(LDDST)和 1mg 过夜地塞米松(ODST)抑制试验在这种情况下的性能。在 2005 年至 2009 年间,我们中心有 125 名患有 AIs 的患者被转介,其中 16 名(12.8%)被诊断为分泌性肾上腺腺瘤。24 名患者(23%)在使用 LDDST 或 ODST 时未能抑制,这两种测试的血清皮质醇截断值均为 50nmol/L;其中 12 例是由于假阳性结果。5 名患者被诊断为肾上腺库欣综合征,7 名患者为亚临床皮质醇增多症。使用较高的 LDDST(83nmol/L)或 ODST(138nmol/L)皮质醇截断值将导致漏诊 1 例库欣综合征和 4 例亚临床皮质醇增多症,或分别漏诊 2 例库欣综合征和 1 例亚临床皮质醇增多症。在接受两种测试的患者中,ODST 系统地导致测试后皮质醇值高于 LDDST。腺瘤直径与 LDDST 后皮质醇相关且具有预测性。我们的结果表明,根据发表的指南改变地塞米松抑制试验后的截断值会改变抑制试验的性能。当用于患有 AIs 的患者时,ODST 可能会导致比 LDDST 更高的测试后皮质醇水平。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验